Sexually Transmitted Diseases (STD) Treatment Market by Service and Geography - Forecast and Analysis 2022-2026

The sexually transmitted diseases (STD) treatment market share is expected to increase by USD 13.48 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 4.27%.

This sexually transmitted diseases treatment market research report provides valuable insights on the post-COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers sexually transmitted diseases (STD) treatment market segmentation by type (viral infections, bacterial infections, and other infections) and geography (North America, Europe, Asia, and Rest of World (ROW)). The sexually transmitted diseases treatment market report also offers information on several market vendors, including AbbVie Inc., Affymetrix, Aurobindo Pharma Ltd., Becton Dickinson and Co., Bristol Myers Squibb Co., C. H. Boehringer Sohn AG and Co. KG, Cepheid Inc., DiaSorin SpA, Dynavax Technologies Corp., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hologic Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson, Lee's Pharmaceutical Holdings Ltd., Lupin Ltd, Merck and Co. Inc., Mylan N.V, and Pfizer Inc. among others.

What will the STD Treatment Market Size be During the Forecast Period?

Download Report Sample to Unlock the Sexually Transmitted Diseases (STD) Treatment Market Size for the Forecast Period and Other Important Statistics

 

STD Treatment Market: Key Drivers, Trends, and Challenges

The increasing prevalence of STDs is notably driving the sexually transmitted diseases treatment market growth, although factors such as limited healthcare services in developing regions may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the sexually transmitted diseases (STD) treatment industry. The holistic analysis of the drivers will help deduce end goals and refine marketing strategies to gain a competitive edge.

Key Sexually Transmitted Diseases (STD) Treatment Market Driver

One of the key factors driving growth in the sexually transmitted diseases treatment market is the increasing prevalence of STDs. STDs are caused by the transmission of different bacteria, viruses, and parasites due to the exchange of vaginal fluids. There are more than 30 different bacteria, viruses, and parasites that can cause STDs. The different types of STDs include syphilis, gonorrhoea, chlamydia, hepatitis B, genital herpes, and HIV/AIDS. STDs can also be caused by HPV and Trichomoniasis vaginalis. Among these, syphilis, gonorrhoea, chlamydia, and trichomoniasis are curable, while hepatitis B, genital herpes, HIV/AIDS, and STDs caused by HPV cannot be cured. The prevalence of these diseases has increased globally. The increasing incidences and prevalence of STDs are increasing the demand for screening and diagnosis of STDs at the earliest to reduce the chances of mortality. Vendors present across the globe are focusing on offering a wide range of STD treatment drugs. Hence, the increasing incidence and prevalence of STDs in several countries across the globe are expected to foster the growth of the global STD treatment market.

Key Sexually Transmitted Diseases (STD) Treatment Market Trend

The advances in rapid diagnosis of STDs are a sexually transmitted diseases (STD) treatment market trend that is expected to have a positive impact in the coming years. There is a significant shift observed from traditional laboratory testing to rapid point-of-care (POC) testing. POC HIV testing is the most accepted method. This method has been implemented to overcome some of the patient and provider barriers to routine screening. The growing preference for self-testing for HIV has been rapidly growing across developed countries. Apart from POC testing, the market is witnessing rapid advances in molecular diagnostics used in STD testing. The market is also witnessing advances in rapid HIV testing as well. Some HIV tests provide accurate results within 5 to 20 minutes. Hence, the availability of such advanced detection techniques is fuels market growth. There are no techniques to diagnose human papillomavirus through blood tests, which is another factor causing a delay in the diagnosis. To overcome this challenge, researchers have been focusing on advancing the diagnosis methods in recent years. Thus, the increasing research on biomarkers and recent advances are expected to ease the diagnosis process, thereby driving the market.

Key Sexually Transmitted Diseases (STD) Treatment Market Challenge

The limited healthcare services in developing regions will be a major challenge for the sexually transmitted diseases (STD) treatment market during the forecast period. A large part of the population in developing regions such as Asia and MEA neither has adequate knowledge about health issues nor access to proper healthcare facilities. This trend is prevalent due to a lack of financial and human resources for medical care, which is a major obstacle in the promotion of public health and leads to a high HIV-infected population. Developing countries such as Kenya, Algeria, Afghanistan, and Bangladesh lack technology, infrastructure, and adequate policies to ensure efficient healthcare service delivery. Also, due to the lack of education, many people face stigma related to STD treatment, such as the misconception that HIV is not a serious threat or embarrassment about undergoing a physical examination. This leads to avoidance of STD treatment and, consequently, the treatment of HIV. These factors lead to an increased prevalence of HIV, resulting in high rates of mortality and morbidity, which, together with the lack of financial resources for infrastructure and health systems, may hinder the growth of the market.

This sexually transmitted diseases treatment market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global pharmaceuticals traceability market as a part of the global pharmaceuticals market within the overall healthcare industry. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the sexually transmitted diseases (STD) treatment market during the forecast period.

Who are the Major STD Treatment Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

 

• AbbVie Inc.
• Affymetrix
• Aurobindo Pharma Ltd.
• Becton Dickinson and Co.
• Bristol Myers Squibb Co.
• C. H. Boehringer Sohn AG and Co. KG
• Cepheid Inc.
• DiaSorin SpA
• Dynavax Technologies Corp.
• F. Hoffmann La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Hologic Inc.
• Inovio Pharmaceuticals Inc.
• Johnson and Johnson
• Lee's Pharmaceutical Holdings Ltd.
• Lupin Ltd
• Merck and Co. Inc.
• Mylan N.V
• Pfizer Inc.

 

This statistical study of the sexually transmitted diseases treatment market encompasses successful business strategies deployed by the key vendors. The sexually transmitted diseases (STD) treatment market is fragmented and the vendors are deploying growth strategies such as distributing their products globally through their subsidiaries and other distribution channels to compete in the market.

Product Insights and News

• abbvie.com - The company offers Sexually Transmitted Diseases Treatment that includes Gardasil 9 which helps to protect against certain cancers and diseases caused by HPV.

• abbvie.com - Under the unified segment, the company conducts research and development, manufacturing, commercialization, and sale of innovative medicines and therapies to allocate resources and assess business performance on a global basis to achieve established long-term strategic goals.

To make the most of the opportunities and recover from the post-COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The sexually transmitted diseases (STD) treatment market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the leading companies' production, sustainability, and prospects.

Sexually Transmitted Diseases (STD) Treatment Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the sexually transmitted diseases treatment market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for the STD Treatment Market?

For more insights on the market share of various regions Request PDF Sample now!

44% of the market’s growth will originate from North America during the forecast period. The US is the key market for sexually transmitted diseases (STD) treatment in North America. Market growth in this region will be faster than the growth of the European market in regions.

The growing prevalence of STDs, a strong presence of vendors such as Johnson and Johnson, Pfizer, AbbVie, and Abbott, and the availability of drugs to treat STDs will facilitate the sexually transmitted diseases treatment market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

North American countries have been severely affected by the outbreak of the COVID-19 pandemic in 2020. The rise in the incidence of COVID-19 across the region influenced governments to introduce emergency legislation, including restrictions on operational activities across various industries. However, post the lifting of lockdowns, an increase in new and rescheduled medical procedures, including STD treatment, raised the demand for STD treatment drugs. Hence, the implementation of vaccination drives, the increasing adoption of STD treatment drugs, a rise in the prevalence of STDs, a rise in healthcare expenditure, and a rise in the number of advanced healthcare facilities for STD treatment are expected to recover and stabilize the growth of the regional market during the forecast period.

What are the Revenue-generating Type Segments in the Sexually Transmitted Diseases (STD) Treatment Market?

To gain further insights on the market contribution of various segments Request PDF Sample

The sexually transmitted diseases (STD) treatment market share growth by the viral infections segment will be significant during the forecast period. The growth of the segment is driven by the increase in the prevalence of STDs caused by viruses. Various STDs caused by viruses include genital infection (human papillomavirus), genital herpes (herpes simplex virus), hepatitis B (hepatitis B virus), and AIDS (HIV). The most common sexually transmitted infections are caused by human papillomavirus worldwide. 

This report provides an accurate prediction of the contribution of all the segments to the growth of the sexually transmitted diseases treatment market size and actionable market insights on the post-COVID-19 impact on each segment.

 

STD Treatment Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 4.27%
Market growth 2022-2026	$13.48 billion
Market structure	Fragmented
YoY growth (%)	3.97
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 44%
Key consumer countries	US, Germany, UK, Japan, and China
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	AbbVie Inc., Affymetrix, Aurobindo Pharma Ltd., Becton Dickinson and Co., Bristol Myers Squibb Co., C. H. Boehringer Sohn AG and Co. KG, Cepheid Inc., DiaSorin SpA, Dynavax Technologies Corp., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hologic Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson, Lee's Pharmaceutical Holdings Ltd., Lupin Ltd, Merck and Co. Inc., Mylan N.V, and Pfizer Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Sexually Transmitted Diseases (STD) Treatment Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive sexually transmitted diseases (STD) treatment market growth during the next five years
• Precise estimation of the sexually transmitted diseases (STD) treatment market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the sexually transmitted diseases (STD) treatment industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of sexually transmitted diseases (STD) treatment market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch